Dr. Rachel Tyndale, CAMH Scientist and Head of Pharmacogenetics in the Neuroscience Department along with Prof. Caryn Lerman at the University of Pennsylvania, are at the helm of a four-year, $12 million (US) National Institute of Health, Pharmacogenomics Research Network-funded study that will continue tackling the serious public health issue of smoking.  

An international team of scientists will focus on understanding how genes impact a person's response to smoking cessation medication.  Their goal - help clinicians choose the best medication for people trying to quit, based on their genes, and improve their response to smoking cessation treatment.

For more information click here.

-30-

The Centre for Addiction and Mental Health (CAMH) is Canada's largest mental health and addiction teaching hospital, as well as one of the world's leading research centres in the area of addiction and mental health. CAMH combines clinical care, research, education, policy development and health promotion to transform the lives of people affected by mental health and addiction issues.  CAMH is fully affiliated with the University of Toronto, and is a Pan American Health Organization/World Health Organization Collaborating Centre.